Business Context and Reporting Period
DSS, INC. (Ticker: DSS) filed its Form 10-Q for the quarterly period ended September 30, 2024. The Company operates nine distinct business lines organized into five reporting segments: Product Packaging, Biotechnology, Direct Marketing, Commercial Lending, and Securities and Investment Management. Notably, the Company deconsolidated Sharing Services Global Corporation (SHRG) effective May 1, 2023, treating its prior operations as discontinued. The Company also completed an Initial Public Offering (IPO) for its subsidiary, Impact BioMedical, Inc., in September 2024.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2024 | Nine Months Ended Sept 30, 2024 |
|---|---|---|
| Total Revenue | $5,599,000 | $13,681,000 |
| Net Loss (Continuing Ops) | $(5,701,000) | $(15,762,000) |
| Net Loss Attributable to Common Stockholders | $(5,283,000) | $(14,034,000) |
| Operating Loss | $(4,671,000) | $(14,287,000) |
| Cash and Cash Equivalents | $11,631,000 | $11,631,000 (Ending Balance) |
| Total Debt (Current + Long-Term) | $57,316,000 | $57,316,000 (Ending Balance) |
| Assets Held for Sale | $46,071,000 | $46,071,000 (Ending Balance) |
Liquidity: The Company reported a net increase in cash of $5,016,000 for the nine months ended September 30, 2024, driven by investing activities (sales of marketable securities and notes receivable) and financing activities (IPO proceeds and debt borrowings), offset by operating cash outflows of $9,181,000.
Material Changes vs. Prior Period
- Revenue: Total revenue increased 34% quarter-over-quarter (Q3 2024 vs. Q3 2023) but decreased 28% year-to-date (YTD 2024 vs. YTD 2023). The Q3 increase was driven by a 46% rise in Printed Products revenue and a 110% increase in Rental income. The YTD decrease was primarily due to a 100% drop in Direct Marketing revenue following the deconsolidation of SHRG and a 61% decline in Rental income.
- Profitability: Net loss attributable to common stockholders improved significantly on a YTD basis, decreasing from $(30,325,000) in 2023 to $(14,034,000) in 2024. This improvement is largely attributed to the absence of the $6,220,000 impairment charge related to SHRG deconsolidation recorded in 2023 and a reduction in the provision for loan losses.
- Debt: Current portion of long-term debt increased to $49,873,000 from $47,776,000 at year-end 2023. Significant portions of debt related to AMRE LifeCare and AMRE Winter Haven are in default and past due.
- Restatement: The Company restated its 2023 financial statements to correct an error regarding the deconsolidation of SHRG, which resulted in a $23.5 million reduction in the previously reported loss for the nine months ended September 30, 2023.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management has concluded that substantial doubt regarding the Company's ability to continue as a going concern has been alleviated. This conclusion is based on $11.6 million in cash, the ability to liquidate $4.1 million in marketable securities, and the planned sale of real estate assets held for sale valued at approximately $46.1 million.
- Unusual Items:
- Debt Defaults: The LifeCare Agreement ($45.1 million outstanding) and Pinnacle Loan ($2.97 million outstanding) are in default with demand for final payment made in December 2023.
- Loan Losses: The Company recorded a provision for loan losses of $908,000 for the nine months ended September 30, 2024, driven by credit weaknesses in specific borrowers (e.g., Puradigm, VEII, BMIC).
- Investment Losses: The Company recorded a loss on investments of $1,021,000 for the nine months ended September 30, 2024, primarily due to unrealized losses on marketable securities.
- Controls and Procedures: The Company disclosed material weaknesses in internal control over financial reporting that remained as of September 30, 2024. Management is implementing a remediation plan, but controls were deemed ineffective.
- Outlook: The Company expects to fund operations for the next 12 months through existing cash, asset sales, and capital raising. Direct Marketing revenue remains low as the business model shifts from a sales force to licensing.
Investor Verification Checklist
- Debt Default Status: Verify the current status of the $48 million+ in defaulted debt (LifeCare and Winter Haven facilities) and any potential foreclosure or restructuring actions.
- Asset Sale Progress: Confirm the timeline and likelihood of selling the $46.1 million in "Assets held for sale" (medical facilities and retail space) to ensure liquidity projections are realistic.
- Loan Portfolio Quality: Review the specific creditworthiness of borrowers in the Commercial Lending segment, particularly those with full or partial reserves (Puradigm, VEII, BMIC).
- Internal Controls: Assess the progress of the remediation plan for material weaknesses in internal controls, which poses a risk to the accuracy of future financial reporting.
- Impact BioMedical IPO: Monitor the trading performance and lock-up expiration (180 days) of the Impact BioMedical subsidiary shares following its September 2024 IPO.